{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:26:38Z","timestamp":1793629598675,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141203"],"award-info":[{"award-number":["82141203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073842"],"award-info":[{"award-number":["82073842"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine"},{"name":"The Science and Technology strategic cooperation Programs of Luzhou Municipal People\u2019s Government and Southwest Medical University"},{"name":"Shanghai Scientific and Innovative Action Plan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Reversing ventricular remodeling represents a promising treatment for the post-myocardial infarction (MI) heart failure (HF). Here, we report a novel small molecule HHQ16, an optimized derivative of\n                    <jats:italic>astragaloside IV<\/jats:italic>\n                    , which effectively reversed infarction-induced myocardial remodeling and improved cardiac function by directly acting on the cardiomyocyte to reverse hypertrophy. The effect of HHQ16 was associated with a strong inhibition of a newly discovered\n                    <jats:italic>Egr2<\/jats:italic>\n                    -affiliated transcript\n                    <jats:italic>lnc9456<\/jats:italic>\n                    in the heart. While minimally expressed in normal mouse heart,\n                    <jats:italic>lnc9456<\/jats:italic>\n                    was dramatically upregulated in the heart subjected to left anterior descending coronary artery ligation (LADL) and in cardiomyocytes subjected to hypertrophic stimulation. The critical role of\n                    <jats:italic>lnc9456<\/jats:italic>\n                    in cardiomyocyte hypertrophy was confirmed by specific overexpression and knockout in vitro. A physical interaction between\n                    <jats:italic>lnc9456<\/jats:italic>\n                    and G3BP2 increased NF-\u03baB nuclear translocation, triggering hypertrophy-related cascades. HHQ16 physically bound to\n                    <jats:italic>lnc9456<\/jats:italic>\n                    with a high-affinity and induced its degradation. Cardiomyocyte-specific\n                    <jats:italic>lnc9456<\/jats:italic>\n                    overexpression induced, but knockout prevented LADL-induced, cardiac hypertrophy and dysfunction. HHQ16 reversed the effect of\n                    <jats:italic>lnc9456<\/jats:italic>\n                    overexpression while lost its protective role when\n                    <jats:italic>lnc9456<\/jats:italic>\n                    was deleted, further confirming\n                    <jats:italic>lnc9456<\/jats:italic>\n                    as the bona fide target of HHQ16. We further identified the human ortholog of\n                    <jats:italic>lnc9456<\/jats:italic>\n                    , also an\n                    <jats:italic>Egr2<\/jats:italic>\n                    -affiliated transcript,\n                    <jats:italic>lnc4012<\/jats:italic>\n                    . Similarly,\n                    <jats:italic>lnc4012<\/jats:italic>\n                    was significantly upregulated in hypertrophied failing hearts of patients with dilated cardiomyopathy. HHQ16 also specifically bound to\n                    <jats:italic>lnc4012<\/jats:italic>\n                    and caused its degradation and antagonized its hypertrophic effects. Targeted degradation of pathological increased\n                    <jats:italic>lnc4012\/lnc9456<\/jats:italic>\n                    by small molecules might serve as a novel promising strategy to regress infarction-induced cardiac hypertrophy and HF.\n                  <\/jats:p>","DOI":"10.1038\/s41392-023-01660-9","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T10:02:20Z","timestamp":1697709740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012\/9456"],"prefix":"10.1038","volume":"8","author":[{"given":"Jingjing","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chennan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saisai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibei","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu Linda","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayue Darrel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"1660_CR1","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz, S. et al. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur. Heart J. 43, 2549\u20132561 (2022).","journal-title":"Eur. Heart J."},{"key":"1660_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387\u2013407 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1660_CR3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1006\/jmcc.1998.0741","volume":"30","author":"CM Kramer","year":"1998","unstructured":"Kramer, C. M. et al. Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. J. Mol. Cell Cardiol. 30, 1773\u20131778 (1998).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1660_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.044313","volume":"142","author":"M Zurek","year":"2020","unstructured":"Zurek, M. et al. Neuregulin-1 induces cardiac hypertrophy and impairs cardiac performance in post-myocardial infarction rats. Circulation 142, 1308\u20131311 (2020).","journal-title":"Circulation"},{"key":"1660_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0002-9149(02)03414-8","volume":"91","author":"H Jilaihawi","year":"2003","unstructured":"Jilaihawi, H. et al. Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. Am. J. Cardiol. 91, 723\u2013726 (2003).","journal-title":"Am. J. Cardiol."},{"key":"1660_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrcardio.2017.139","volume":"15","author":"GH Kim","year":"2018","unstructured":"Kim, G. H., Uriel, N. & Burkhoff, D. Reverse remodelling and myocardial recovery in heart failure. Nat. Rev. Cardiol. 15, 83\u201396 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1660_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11886-017-0876-4","volume":"19","author":"AS Bhatt","year":"2017","unstructured":"Bhatt, A. S., Ambrosy, A. P. & Velazquez, E. J. Adverse remodeling and reverse remodeling after myocardial infarction. Curr. Cardiol. Rep. 19, 71 (2017).","journal-title":"Curr. Cardiol. Rep."},{"key":"1660_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41569-022-00806-6","volume":"20","author":"TG Martin","year":"2023","unstructured":"Martin, T. G., Juarros, M. A. & Leinwand, L. A. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat. Rev. Cardiol. 20, 347\u2013363 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"1660_CR9","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/ehf2.13285","volume":"8","author":"M-G Moon","year":"2021","unstructured":"Moon, M.-G. et al. Reverse remodelling by sacubitril\/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Heart Fail. 8, 2058\u20132069 (2021).","journal-title":"ESC Heart Fail."},{"key":"1660_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.CIR.98.7.656","volume":"98","author":"A Zafeiridis","year":"1998","unstructured":"Zafeiridis, A., Jeevanandam, V., Houser, S. R. & Margulies, K. B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98, 656\u2013662 (1998).","journal-title":"Circulation"},{"key":"1660_CR11","first-page":"502","volume":"104","author":"JRDAR Reis Filho","year":"2015","unstructured":"Reis Filho, J. R. D. A. R., Cardoso, J. N., Cardoso, C. M. D. R. & Pereira-Barretto, A. C. Reverse cardiac remodeling: a marker of better prognosis in heart failure. Arq. Bras. Cardiol. 104, 502\u2013506 (2015).","journal-title":"Arq. Bras. Cardiol."},{"key":"1660_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/24748706.2021.1954275","volume":"5","author":"J Boulet","year":"2021","unstructured":"Boulet, J. & Mehra, M. R. Left ventricular reverse remodeling in heart failure: remission to recovery. Structural Heart 5, 466\u2013481 (2021).","journal-title":"Structural Heart"},{"key":"1660_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/ph15070875","volume":"15","author":"H Xia","year":"2022","unstructured":"Xia, H. et al. Na+\/H+ exchanger 1, a potential therapeutic drug target for cardiac hypertrophy and heart failure. Pharmaceuticals 15, 875 (2022).","journal-title":"Pharmaceuticals"},{"key":"1660_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","volume":"8","author":"TG von Lueder","year":"2015","unstructured":"von Lueder, T. G. et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ. Heart Fail. 8, 71\u201378 (2015).","journal-title":"Circ. Heart Fail."},{"key":"1660_CR15","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/CIRCULATIONAHA.106.656835","volume":"115","author":"H-L Li","year":"2007","unstructured":"Li, H.-L. et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115, 1885\u20131894 (2007).","journal-title":"Circulation"},{"key":"1660_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pathophys.2018.04.003","volume":"25","author":"D Gabriel-Costa","year":"2018","unstructured":"Gabriel-Costa, D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology 25, 277\u2013284 (2018).","journal-title":"Pathophysiology"},{"key":"1660_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1139\/cjpp-2019-0566","volume":"98","author":"CJ Oldfield","year":"2020","unstructured":"Oldfield, C. J., Duhamel, T. A. & Dhalla, N. S. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can. J. Physiol. Pharmacol. 98, 74\u201384 (2020).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"1660_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/jpet.114.217091","volume":"351","author":"A Kili\u0107","year":"2014","unstructured":"Kili\u0107, A. et al. Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation. J. Pharmacol. Exp. Ther. 351, 492\u2013499 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1660_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.yjmcc.2018.12.010","volume":"127","author":"S Tamura","year":"2019","unstructured":"Tamura, S., Marunouchi, T. & Tanonaka, K. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway. J. Mol. Cell Cardiol. 127, 134\u2013142 (2019).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1660_CR20","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1111\/jcmm.13713","volume":"22","author":"L Yuan","year":"2018","unstructured":"Yuan, L. et al. Heat-shock transcription factor 1 is critically involved in the ischaemia-induced cardiac hypertrophy via JAK2\/STAT3 pathway. J. Cell Mol. Med. 22, 4292\u20134303 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"1660_CR21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/ejhf.1813","volume":"22","author":"A Garg","year":"2020","unstructured":"Garg, A. et al. MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling. Eur. J. Heart Fail. 22, 1366\u20131377 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1660_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrd2193","volume":"6","author":"TA McKinsey","year":"2007","unstructured":"McKinsey, T. A. & Kass, D. A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 6, 617\u2013635 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1660_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4109-6","volume":"21","author":"Z Luo","year":"2020","unstructured":"Luo, Z. et al. Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart disease: a randomized controlled trial protocol. Trials 21, 267 (2020).","journal-title":"Trials"},{"key":"1660_CR24","doi-asserted-by":"publisher","first-page":"659707","DOI":"10.3389\/fphar.2021.659707","volume":"12","author":"S Lin","year":"2021","unstructured":"Lin, S. et al. Efficacy and safety of traditional Chinese medicine injections for heart failure with reduced ejection fraction: a bayesian network meta-analysis of randomized controlled trials. Front. Pharmacol. 12, 659707 (2021).","journal-title":"Front. Pharmacol."},{"key":"1660_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/med.21785","volume":"41","author":"H-F Su","year":"2021","unstructured":"Su, H.-F. et al. Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix). Med. Res. Rev. 41, 1999\u20132038 (2021).","journal-title":"Med. Res. Rev."},{"key":"1660_CR26","doi-asserted-by":"publisher","first-page":"110012","DOI":"10.1016\/j.biopha.2020.110012","volume":"126","author":"Y Zang","year":"2020","unstructured":"Zang, Y. et al. An updated role of astragaloside IV in heart failure. Biomed. Pharmacother. 126, 110012 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1660_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11655-011-0756-5","volume":"17","author":"S Lu","year":"2011","unstructured":"Lu, S., Chen, K.-j, Yang, Q.-y & Sun, H.-r Progress in the research of Radix Astragali in treating chronic heart failure: effective ingredients, dose-effect relationship and adverse reaction. Chin. J. Integr. Med. 17, 473\u2013477 (2011).","journal-title":"Chin. J. Integr. Med."},{"key":"1660_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/FJC.0000000000000437","volume":"69","author":"C Wang","year":"2017","unstructured":"Wang, C. et al. Tetramethylpyrazine and astragaloside IV synergistically ameliorate left ventricular remodeling and preserve cardiac function in a rat myocardial infarction model. J. Cardiovasc. Pharmacol. 69, 34\u201340 (2017).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1660_CR29","doi-asserted-by":"publisher","first-page":"BSR20171036","DOI":"10.1042\/BSR20171036","volume":"38","author":"B Tang","year":"2018","unstructured":"Tang, B., Zhang, J.-G., Tan, H.-Y. & Wei, X.-Q. Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure. Biosci. Rep. 38, BSR20171036 (2018).","journal-title":"Biosci. Rep."},{"key":"1660_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cardiores.2004.10.014","volume":"65","author":"XM Gao","year":"2005","unstructured":"Gao, X. M. et al. Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc. Res. 65, 469\u2013477 (2005).","journal-title":"Cardiovasc. Res."},{"key":"1660_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","volume":"172","author":"F Kopp","year":"2018","unstructured":"Kopp, F. & Mendell, J. T. Functional classification and experimental dissection of long noncoding RNAs. Cell 172, 393\u2013407 (2018).","journal-title":"Cell"},{"key":"1660_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-biochem-062917-012708","volume":"89","author":"JL Rinn","year":"2020","unstructured":"Rinn, J. L. & Chang, H. Y. Long noncoding RNAs: molecular modalities to organismal functions. Ann. Rev. Biochem. 89, 283\u2013308 (2020).","journal-title":"Ann. Rev. Biochem."},{"key":"1660_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/aps.2017.58","volume":"39","author":"HQ Hong","year":"2018","unstructured":"Hong, H. Q. et al. G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-\u03baB signaling pathway. Acta Pharmacol. Sin. 39, 184\u2013194 (2018).","journal-title":"Acta Pharmacol. Sin."},{"key":"1660_CR34","doi-asserted-by":"publisher","first-page":"36441","DOI":"10.1074\/jbc.M004751200","volume":"275","author":"M Prigent","year":"2000","unstructured":"Prigent, M., Barlat, I., Langen, H. & Dargemont, C. IkappaBalpha and IkappaBalpha \/NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2. J. Biol. Chem. 275, 36441\u201336449 (2000).","journal-title":"J. Biol. Chem."},{"key":"1660_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature13596","volume":"514","author":"P Han","year":"2014","unstructured":"Han, P. et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102\u2013106 (2014).","journal-title":"Nature"},{"key":"1660_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCULATIONAHA.121.054827","volume":"144","author":"D Zhao","year":"2021","unstructured":"Zhao, D. et al. Targeting E3 ubiquitin ligase WWP1 prevents cardiac hypertrophy through destabilizing DVL2 via inhibition of K27-linked ubiquitination. Circulation 144, 694\u2013711 (2021).","journal-title":"Circulation"},{"key":"1660_CR37","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/cvr\/cvz111","volume":"115","author":"DWD Kuster","year":"2019","unstructured":"Kuster, D. W. D. et al. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy. Cardiovasc. Res. 115, 1986\u20131997 (2019).","journal-title":"Cardiovasc. Res."},{"key":"1660_CR38","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.7150\/thno.50990","volume":"11","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure. Theranostics 11, 7995\u20138007 (2021).","journal-title":"Theranostics"},{"key":"1660_CR39","doi-asserted-by":"publisher","first-page":"H381","DOI":"10.1152\/ajpheart.00602.2003","volume":"286","author":"L Chen","year":"2004","unstructured":"Chen, L. et al. Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition. Am. J. Physiol. Heart Circ. Physiol. 286, H381\u2013H387 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1660_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/eurjhf\/hfq205","volume":"13","author":"M Shafazand","year":"2011","unstructured":"Shafazand, M. et al. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993\u20132004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur. J. Heart Fail. 13, 135\u2013141 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"1660_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/FJC.0000000000000126","volume":"64","author":"E Bisping","year":"2014","unstructured":"Bisping, E., Wakula, P., Poteser, M. & Heinzel, F. R. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J. Cardiovasc. Pharmacol. 64, 293\u2013305 (2014).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1660_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41569-022-00756-z","volume":"20","author":"R Kamel","year":"2023","unstructured":"Kamel, R., Leroy, J., Vandecasteele, G. & Fischmeister, R. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nat. Rev. Cardiol. 20, 90\u2013108 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"1660_CR43","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm.4179","volume":"22","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat. Med. 22, 1131\u20131139 (2016).","journal-title":"Nat. Med."},{"key":"1660_CR44","doi-asserted-by":"publisher","first-page":"326ra322","DOI":"10.1126\/scitranslmed.aaf1475","volume":"8","author":"J Viereck","year":"2016","unstructured":"Viereck, J. et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci. Transl. Med. 8, 326ra322 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1660_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCRESAHA.117.310624","volume":"121","author":"MT Piccoli","year":"2017","unstructured":"Piccoli, M. T. et al. Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circ. Res. 121, 575\u2013583 (2017).","journal-title":"Circ. Res."},{"key":"1660_CR46","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1093\/eurheartj\/ehaa519","volume":"41","author":"J Viereck","year":"2020","unstructured":"Viereck, J. et al. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. Eur. Heart J. 41, 3462\u20133474 (2020).","journal-title":"Eur. Heart J."},{"key":"1660_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-022-04537-z","volume":"604","author":"R Aguilar","year":"2022","unstructured":"Aguilar, R. et al. Targeting Xist with compounds that disrupt RNA structure and X inactivation. Nature 604, 160\u2013166 (2022).","journal-title":"Nature"},{"key":"1660_CR48","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bbamcr.2018.09.001","volume":"1866","author":"U Alam","year":"2019","unstructured":"Alam, U. & Kennedy, D. Rasputin a decade on and more promiscuous than ever? A review of G3BPs. Biochim. Biophys. Acta Mol. Cell Res. 1866, 360\u2013370 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1660_CR49","doi-asserted-by":"publisher","first-page":"718548","DOI":"10.3389\/fimmu.2021.718548","volume":"12","author":"W Kang","year":"2021","unstructured":"Kang, W. et al. Research progress on the structure and function of G3BP. Front. Immunol. 12, 718548 (2021).","journal-title":"Front. Immunol."},{"key":"1660_CR50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra, S. & Kass, D. A. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 18, 400\u2013423 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1660_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/cvr\/cvq274","volume":"89","author":"T Hamid","year":"2011","unstructured":"Hamid, T. et al. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc. Res. 89, 129\u2013138 (2011).","journal-title":"Cardiovasc. Res."},{"key":"1660_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/01.CIR.0000085362.40608.DD","volume":"108","author":"NH Purcell","year":"2003","unstructured":"Purcell, N. H. & Molkentin, J. D. Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation 108, 638\u2013640 (2003).","journal-title":"Circulation"},{"key":"1660_CR53","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy, S. P., Ibrahim, N. E. & Januzzi, J. L. Heart failure with reduced ejection fraction: a review. JAMA 324, 488\u2013504 (2020).","journal-title":"JAMA"},{"key":"1660_CR54","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.apsb.2020.10.017","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression. Acta Pharm. Sin. B 11, 680\u2013693 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"1660_CR55","doi-asserted-by":"publisher","first-page":"106887","DOI":"10.1016\/j.vascn.2020.106887","volume":"104","author":"C Li","year":"2020","unstructured":"Li, C., Rong, X., Qin, J. & Wang, S. An improved two-step method for extraction and purification of primary cardiomyocytes from neonatal mice. J. Pharmacol. Toxicol. Methods 104, 106887 (2020).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"1660_CR56","doi-asserted-by":"publisher","first-page":"105118","DOI":"10.1016\/j.phrs.2020.105118","volume":"161","author":"J Wan","year":"2020","unstructured":"Wan, J. et al. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance. Pharmacol. Res. 161, 105118 (2020).","journal-title":"Pharmacol. Res."},{"key":"1660_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41401-021-00666-9","volume":"43","author":"P-Y Wang","year":"2022","unstructured":"Wang, P.-Y. et al. The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathway. Acta Pharmacol. Sin. 43, 367\u2013375 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"1660_CR58","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1172\/JCI97965","volume":"128","author":"Y Zou","year":"2018","unstructured":"Zou, Y. et al. Long noncoding RNA LERFS negatively regulates rheumatoid synovial aggression and proliferation. J. Clin. Invest. 128, 4510\u20134524 (2018).","journal-title":"J. Clin. Invest."},{"key":"1660_CR59","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.apsb.2021.05.009","volume":"11","author":"R Huang","year":"2021","unstructured":"Huang, R. et al. Bruceine D inhibits HIF-1-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT\/-catenin interaction. Acta Pharm. Sin. B 11, 3481\u20133492 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"1660_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1251\/bpo35","volume":"4","author":"A Klotzbucher","year":"2002","unstructured":"Klotzbucher, A., Pascreau, G., Prigent, C. & Arlot-Bonnemains, Y. A method for analyzing the ubiquitination and degradation of aurora-A. Biol. Proced. Online 4, 62\u201369 (2002).","journal-title":"Biol. Proced. Online"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01660-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:03:10Z","timestamp":1700373790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01660-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1660"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01660-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"414"}}